GRM5 (Glutamate Metabotropic Receptor 5) encodes the group I metabotropic glutamate receptor mGluR5, a G-protein coupled receptor that plays a central role in synaptic plasticity, learning, memory, and cellular excitotoxicity. mGluR5 is widely expressed throughout the brain, particularly in the hippocampus, cortex, striatum, and basal ganglia. This receptor has emerged as a critical therapeutic target for Alzheimer's disease, Parkinson's disease, and other neurological disorders due to its involvement in amyloid-beta toxicity, excitotoxic cell death, and synaptic dysfunction.
The metabotropic glutamate receptor family consists of eight members (GRM1-8) divided into three groups based on sequence homology, signal transduction mechanisms, and pharmacological profiles. GRM5 belongs to group I, which also includes GRM1 (mGluR1). These receptors are primarily postsynaptic and couple to Gq proteins, leading to activation of phospholipase C and subsequent intracellular calcium release. This makes mGluR5 a key player in activity-dependent synaptic plasticity but also a potential mediator of pathological calcium dysregulation in neurodegeneration.
| Property |
Value |
| Gene Symbol |
GRM5 |
| Protein |
mGluR5 protein |
| Chromosomal Location |
11q14.2 |
| NCBI Gene ID |
2915 |
| UniProt ID |
P41594 |
| Aliases |
GLUR5, mGlu5, GPRC1E |
| Gene Family |
Class C GPCR, metabotropic glutamate receptors |
| Exon Count |
10 exons |
| Transcript Length |
6.1 kb |
Group I mGlu receptors (mGluR1 and mGluR5) are predominantly postsynaptic and couple to Gq proteins, initiating a cascade of intracellular signaling events that profoundly influence neuronal function:
- Phospholipase C activation: Activates PLCβ, cleaving phosphatidylinositol 4,5-bisphosphate (PIP2)
- Calcium release: Generates IP3, leading to Ca²⁺ release from endoplasmic reticulum stores
- Protein kinase C activation: DAG activates PKC, phosphorylating numerous targets
- MAPK/ERK pathway: Triggers downstream kinase cascades
- NMDA receptor modulation: Modulates NMDA receptor activity and trafficking
mGluR5 exhibits widespread brain distribution:
- Hippocampus: Highest expression in CA1-CA3 regions, particularly in dendritic fields
- Cortex: High expression in layers II-III and V, in both pyramidal and interneurons
- Striatum: Moderate expression in medium spiny neurons
- Basal ganglia: Expression in substantia nigra pars reticulata
- Thalamus: High expression in relay nuclei
- Cerebellum: Lower expression, primarily in Purkinje cells
- Synaptic plasticity: Critical for both LTP and LTD induction
- Learning and memory: Hippocampal mGluR5 is essential for contextual learning
- Cognitive function: Modulates working memory and executive function
- Emotional processing: Involvement in anxiety and depression-related behaviors
- Motor coordination: Cerebellar mGluR5 participates in motor learning
mGluR5 has complex and context-dependent roles in Alzheimer's disease, acting both as a mediator of amyloid-beta toxicity and as a potential therapeutic target:
- Functional receptor: mGluR5 serves as a functional receptor for amyloid-beta oligomers, mediating synaptic toxicity
- Oligomer binding: Aβ oligomers bind to mGluR5, triggering aberrant signaling cascades
- Synaptic dysfunction: Activation of mGluR5 by Aβ oligomers contributes to synapse elimination
- Memory impairment: mGluR5 antagonists improve cognitive function in AD models
- Hyperactivation: Aβ-induced mGluR5 activation leads to calcium overload
- Excitotoxicity: Elevated intracellular Ca²⁺ triggers excitotoxic cell death pathways
- Endoplasmic reticulum stress: Ca²⁺ dysregulation causes ER stress
- Mitochondrial dysfunction: Ca²⁺ overload damages mitochondria
- Synapse elimination: Aberrant mGluR5 signaling contributes to dendritic spine loss
- Long-term depression: Excessive LTD-like mechanisms may underlie synaptic loss
- Network dysfunction: Altered mGluR5 signaling disrupts hippocampal-cortical networks
- Antagonists: mGluR5 antagonists protect against Aβ toxicity
- PET tracers: [11C]ABP688 and similar ligands for imaging mGluR5 in AD
- Clinical trials: mGluR5 antagonists tested in AD clinical trials
mGluR5 plays significant roles in Parkinson's disease pathogenesis and levodopa-induced dyskinesias:
- Dopaminergic neuron death: Overactivation contributes to excitotoxic dopaminergic neuron death
- Subthalamic nucleus: mGluR5 contributes to pathological firing patterns
- Striatal medium spiny neurons: Altered signaling in PD models
- Dyskinesia development: Chronic levodopa treatment leads to mGluR5 sensitization
- Striatal signaling: Abnormal mGluR5-PKC-DARPP32 signaling
- Therapeutic benefit: mGluR5 antagonists reduce dyskinesias in PD models
- Basal ganglia modulation: mGluR5 affects motor output through striatal mechanisms
- Substantia nigra: May contribute to progressive dopaminergic neuron loss
mGluR5 is a promising therapeutic target in Huntington's disease:
- Excitotoxic mechanisms: mGluR5 overactivation contributes to neuronal death
- Mutant huntingtin: Alters mGluR5 signaling and trafficking
- Neuroprotective effects: mGluR5 antagonists show protective effects in HD models
- Motor improvement: mGluR5 blockade improves motor performance
- Excitotoxic mechanisms: Contributes to motor neuron excitotoxicity
- Calcium dysregulation: Exacerbates Ca²⁺ overload in motor neurons
- Potential therapy: mGluR5 antagonists may protect motor neurons
- mGluR5 theory: The "mGluR5 theory of Fragile X" proposes that mGluR5 hyperactivity is a central mechanism
- Synaptic plasticity: Enhanced mGluR5-dependent LTD in FXS models
- Therapeutic implications: mGluR5 antagonists (like mavoglurant) have been tested in clinical trials
mGluR5 activates multiple downstream signaling cascades:
Glutamate (postsynaptic) → mGluR5 → Gq protein
↓
Phospholipase C (PLCβ)
↓
┌────────────────┼────────────────┐
↓ ↓ ↓
PIP2 cleavage DAG generation IP3 production
↓ ↓ ↓
PKC activation PKC activation ER Ca²⁺ release
↓ ↓ ↓
┌──────────┼──────────┐ ↓ ↓
↓ ↓ ↓ ↓ ↓
MAPK/ERK CREB Gene Multiple effects:
pathway transcription transcription
↓ ↓ ↓
Synaptic Memory Protein
plasticity formation synthesis
| Interactor |
Interaction Type |
Functional Effect |
| mGluR5 protein |
Homodimerization |
Receptor function and trafficking |
| APP/Aβ |
Physical binding |
Aβ toxicity mediation |
| GRIN1 (NMDA NR1) |
Physical interaction |
NMDA modulation |
| GRIN2A (NMDA NR2A) |
Physical interaction |
Synaptic plasticity |
| HOMER1/2/3 |
PDZ domain |
Synaptic anchoring |
| PICK1 |
PDZ domain |
Trafficking |
| RACK1 |
Scaffold |
Signaling complex |
| SHANK proteins |
Scaffold |
Postsynaptic density |
| GRIP1/2 |
PDZ domain |
Receptor clustering |
| Norbin |
Cytoplasmic protein |
Receptor trafficking |
- Synthesis: mGluR5 is synthesized in the endoplasmic reticulum as monomers
- Dimerization: Forms functional homodimers in the ER
- Glycosylation: Undergoes N-linked glycosylation in the Golgi
- Surface expression: Traffics to the plasma membrane
- Synaptic targeting: Anchored at postsynaptic densities via HOMER proteins
- Endocytosis: Internalized in an activity-dependent manner
- Recycling: Can be recycled back to the membrane or targeted for degradation
mGluR5 has well-characterized allosteric binding sites:
- MPEP site: Allosteric antagonist binding site
- MTEP site: High-affinity antagonist binding
- CDPPB site: Positive allosteric modulators (PAMs)
- Fenobam site: Clinical antagonist candidate
mGluR5 forms multiprotein signaling complexes:
- Homer scaffolds: Connect mGluR5 to NMDA receptors and intracellular Ca²⁺ stores
- Shank complexes: Organize the postsynaptic density
- RACK1: Scaffold for signaling molecules
- Norbin: Regulates receptor trafficking
| Compound |
Development Stage |
Key Features |
| MTEP |
Preclinical/Clinical |
Selective mGluR5 antagonist |
| MPEP |
Research tool |
First-generation antagonist |
| Fenobam |
Clinical candidate |
Anxiolytic, tested in humans |
| Mavoglurant |
Clinical trials |
Tested in FXS and PD |
| AZD2066 |
Clinical trials |
Clinical candidate |
| R213 |
Preclinical |
Highly selective |
| Ligand |
Status |
Use |
| [11C]ABP688 |
Research |
mGluR5 PET imaging |
| [18F]FPEB |
Research |
mGluR5 quantification |
| [11C]CTS-1 |
Research |
mGluR5 PET |
- mGluR5 antagonists have been tested in clinical trials for:
- Development for neurodegeneration remains in preclinical to early clinical stages
- Challenges include side effects (including hallucinations) and optimal dosing
mGluR5 modulators may be combined with:
- Acetylcholinesterase inhibitors: Potential synergistic cognitive benefits
- NMDA antagonists: Combined effects on excitotoxicity
- Antiamyloid therapies: Complementary mechanisms
- Rodent vs. human: Differences in agonist potency and allosteric site pharmacology
- Expression patterns: Some species-specific regional distributions
- Alternative splicing: Species-specific splice variants
The GRM5 gene shows conservation across vertebrates:
- Orthologs present in all mammalian species
- Fish and amphibian orthologs characterized
- Evolutionary relationship to other group I mGlu receptors
- CRISPR-Cas9: Generation of GRM5 knockout cells
- RNAi: knockdown of GRM5 expression
- Fluorescent reporters: Live-cell imaging
- Biosensors: Calcium and IP3 sensors
- GRM5 knockout mice: Complete loss of mGluR5 expression
- Conditional knockouts: Tissue-specific deletion
- Transgenic reporters: GFP-tagged expression
- Electrophysiology: Patch-clamp recordings
- Calcium imaging: Live-cell measurements
- Behavior: Cognitive testing
- Histology: Brain tissue analysis
- Selective compounds: Need for highly selective mGluR5 modulators
- Safe clinical candidates: Reduce CNS side effects
- Biomarkers: PET ligands to monitor target engagement
- Patient selection: Identify responsive patient populations
- Novel antagonists: New chemotypes with improved safety
- Biomarker development: PET ligands for clinical development
- Combination approaches: mGluR5 with other disease-modifying therapies
- Target engagement: Better ways to measure receptor occupancy